HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment


如何引用文章

全文:

详细

The main method of treatment patients with disseminated gastric cancer is drug therapy. Trastuzumab has proven its efficacy in therapyHER2-positive gastric cancer in combination with chemotherapy. In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival and, therefore, is required to treat these patients.

作者简介

N Besova

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

канд. мед. наук, ст. науч. сотр. отд-ния химиотерапии

参考

  1. Wagner A.D, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2010; 3: CD004064. DOI: http://10.1002/14651858.CD004064.pub3
  2. Ajani J.A, Rodriquez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first - line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. JCO 2009; 27: 15s (Suppl., abstr. 4511).
  3. Kang Y, Kang W.K, Shin D.B et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion jo 5-FU/cisplatin (FP) as first - line therapy in patient with advanced gastric cancer: Efficacy and safety results. J Clin Oncol 2006; 24: 18S. Abstr. 4018.
  4. Dank M, Zaluski J, Barone C et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st - line advanced gastric cancer patients. Proc Am Soc Clin Oncol 2005; 23 (16s): 308s. Abstr. 4003.
  5. Ajani J.A, Podor M, van Cutsem E et al. Multinational randomised phase 11 trial of docetaxel (T) and cisplatin with or without 5-fluorouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC). Proc Am Soc Clin Oncol 2000; 19: 247a (Abstr. 957).
  6. Cunnigham D, Rao S, Starling N et al. Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: The REAL 2 trial. J Clin Oncol; 24: 18S. Abstr. 4001.
  7. Bass A.J. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 10.1038/nature13480' target='_blank'>http://doi: 10.1038/nature13480
  8. Tan I.B, Ivanova T, Lim K.H et al. Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology 2011; 141: 476-85.
  9. Ung L, Chua T.C, Merrett N.D. Targeting HER2-amplifications in gastric cancer. Gastrointestinal Cancer: Targets Therapy 2014; 4: 11-22.
  10. Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy vs. chemotherapy alone for treatment of HER2-positive advanced gastric or gastro - oesophageal junction cancer (ToGA): a phase 3, open - label, randomised controlled trial. Lancet 2010; 376: 687-97.
  11. Bang Y-J. A randomized, open - label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second - line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J Clin Oncol 2012; 30: (suppl. 34; abstr. 11).
  12. Hecht J.R et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO- 013/LOGiC Trial. JCO 2013 ASCO Annual Meeting Abstracts 2013; 31 (18). Suppl. LBA4001.

版权所有 © Consilium Medicum, 2014

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##